Printer Friendly Version View printer-friendly version
<< Back
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018

ACADIA to Host Conference Call and Webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Oct. 23, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September 30, 2018 on Tuesday, November 6, 2018, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.

The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 3659459). A telephone replay of the conference call may be accessed through November 20, 2018 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 3659459). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com under the investors section and will be archived there until November 20, 2018.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2017 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
Elena Ridloff, CFA
(858) 558-2871
ir@acadia-pharm.com